240 related articles for article (PubMed ID: 31054432)
41. Type IIA - Type IIB protein tyrosine kinase inhibitors hybridization as an efficient approach for potent multikinase inhibitor development: Design, synthesis, anti-proliferative activity, multikinase inhibitory activity and molecular modeling of novel indolinone-based ureides and amides.
Eldehna WM; El Kerdawy AM; Al-Ansary GH; Al-Rashood ST; Ali MM; Mahmoud AE
Eur J Med Chem; 2019 Feb; 163():37-53. PubMed ID: 30503942
[TBL] [Abstract][Full Text] [Related]
42. Synthesis and in vitro anticancer evaluation of some fused indazoles, quinazolines and quinolines as potential EGFR inhibitors.
Abdelsalam EA; Zaghary WA; Amin KM; Abou Taleb NA; Mekawey AAI; Eldehna WM; Abdel-Aziz HA; Hammad SF
Bioorg Chem; 2019 Aug; 89():102985. PubMed ID: 31121559
[TBL] [Abstract][Full Text] [Related]
43. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation.
Abdallah AE; Eissa SI; Al Ward MMS; Mabrouk RR; Mehany ABM; El-Zahabi MA
Bioorg Chem; 2021 Apr; 109():104695. PubMed ID: 33647743
[TBL] [Abstract][Full Text] [Related]
44. Design, Synthesis, and Cytotoxic Evaluation of Certain 7-Chloro-4-(piperazin-1-yl)quinoline Derivatives as VEGFR-II Inhibitors.
Aboul-Enein MN; El-Azzouny AM; Ragab FA; Hamissa MF
Arch Pharm (Weinheim); 2017 Apr; 350(3-4):. PubMed ID: 28304102
[TBL] [Abstract][Full Text] [Related]
45. Synthesis of some quinazolinones inspired from the natural alkaloid L
Ghorab MM; Abdel-Kader MS; Alqahtani AS; Soliman AM
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):218-237. PubMed ID: 33357002
[TBL] [Abstract][Full Text] [Related]
46. Molecular Design and Synthesis of New 3,4-Dihydropyrimidin-2(1H)-Ones as Potential Anticancer Agents with VEGFR-2 Inhibiting Activity.
Mostafa AS; Bayoumi WA; El-Mesery M; Elgaml A
Anticancer Agents Med Chem; 2019; 19(3):310-322. PubMed ID: 30019649
[TBL] [Abstract][Full Text] [Related]
47. Benzo[g]quinazolin-based scaffold derivatives as dual EGFR/HER2 inhibitors.
Ghorab MM; Alsaid MS; Soliman AM; Al-Mishari AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):67-73. PubMed ID: 29098904
[TBL] [Abstract][Full Text] [Related]
48. Design, synthesis, and molecular docking of novel indole scaffold-based VEGFR-2 inhibitors as targeted anticancer agents.
Roaiah HM; Ghannam IAY; Ali IH; El Kerdawy AM; Ali MM; Abbas SE; El-Nakkady SS
Arch Pharm (Weinheim); 2018 Feb; 351(2):. PubMed ID: 29323750
[TBL] [Abstract][Full Text] [Related]
49. In Vitro and In Silico Evaluation of Anticancer Activity of New Indole-Based 1,3,4-Oxadiazoles as EGFR and COX-2 Inhibitors.
Sever B; Altıntop MD; Özdemir A; Akalın Çiftçi G; Ellakwa DE; Tateishi H; Radwan MO; Ibrahim MAA; Otsuka M; Fujita M; Ciftci HI; Ali TFS
Molecules; 2020 Nov; 25(21):. PubMed ID: 33171861
[TBL] [Abstract][Full Text] [Related]
50. Design and synthesis of novel (S)-Naproxen hydrazide-hydrazones as potent VEGFR-2 inhibitors and their evaluation in vitro/in vivo breast cancer models.
Han Mİ; Atalay P; Tunç CÜ; Ünal G; Dayan S; Aydın Ö; Küçükgüzel ŞG
Bioorg Med Chem; 2021 May; 37():116097. PubMed ID: 33743356
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
52. Design, Synthesis, Cytotoxic Evaluation and Molecular Docking of New Fluoroquinazolinones as Potent Anticancer Agents with Dual EGFR Kinase and Tubulin Polymerization Inhibitory Effects.
Zayed MF; Ahmed S; Ihmaid S; Ahmed HEA; Rateb HS; Ibrahim SRM
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29891789
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and Molecular modeling study of certain EGFRinhibitors with a quinazolinone scaffold as anti-hepatocellular carcinoma and Radio-sensitizers.
Ghorab WM; El-Sebaey SA; Ghorab MM
Bioorg Chem; 2023 Feb; 131():106310. PubMed ID: 36528923
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, and SAR studies of novel 4-methoxyphenyl pyrazole and pyrimidine derivatives as potential dual tyrosine kinase inhibitors targeting both EGFR and VEGFR-2.
El-Naggar AM; Hassan AMA; Elkaeed EB; Alesawy MS; Al-Karmalawy AA
Bioorg Chem; 2022 Jun; 123():105770. PubMed ID: 35395446
[TBL] [Abstract][Full Text] [Related]
55. Synthesis, Molecular Modeling and Biological Evaluation of 4-Alkoxyquinazoline Derivatives as Novel Inhibitors of VEGFR2.
Lu L; Zhao TT; Liu TB; Sun WX; Xu C; Li DD; Zhu HL
Chem Pharm Bull (Tokyo); 2016 Nov; 64(11):1570-1575. PubMed ID: 27568484
[TBL] [Abstract][Full Text] [Related]
56. New oxadiazoles with selective-COX-2 and EGFR dual inhibitory activity: Design, synthesis, cytotoxicity evaluation and in silico studies.
El-Sayed NA; Nour MS; Salem MA; Arafa RK
Eur J Med Chem; 2019 Dec; 183():111693. PubMed ID: 31539778
[TBL] [Abstract][Full Text] [Related]
57. New 2,4-disubstituted-2-thiopyrimidines as VEGFR-2 inhibitors: Design, synthesis, and biological evaluation.
Abdel-Mohsen HT; Girgis AS; Mahmoud AEE; Ali MM; El Diwani HI
Arch Pharm (Weinheim); 2019 Nov; 352(11):e1900089. PubMed ID: 31463965
[TBL] [Abstract][Full Text] [Related]
58. Design and synthesis of thienopyrimidine urea derivatives with potential cytotoxic and pro-apoptotic activity against breast cancer cell line MCF-7.
Abdelhaleem EF; Abdelhameid MK; Kassab AE; Kandeel MM
Eur J Med Chem; 2018 Jan; 143():1807-1825. PubMed ID: 29133058
[TBL] [Abstract][Full Text] [Related]
59. Benzoxazole/benzothiazole-derived VEGFR-2 inhibitors: Design, synthesis, molecular docking, and anticancer evaluations.
El-Helby AA; Sakr H; Eissa IH; Al-Karmalawy AA; El-Adl K
Arch Pharm (Weinheim); 2019 Dec; 352(12):e1900178. PubMed ID: 31596514
[TBL] [Abstract][Full Text] [Related]
60. Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR: Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies.
Bilal MS; Ejaz SA; Zargar S; Akhtar N; Wani TA; Riaz N; Aborode AT; Siddique F; Altwaijry N; Alkahtani HM; Umar HI
Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36358960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]